Jupiter, FL (Scicasts) — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy.
The new ADC technology advances a class of pharmaceuticals that use antibodies to selectively deliver drugs to cancer cells without harming healthy cells and tissues.
The study, published online this week in the journal Nature Communications, was led by TSRI Associate Professor Christoph Rader and TSRI Professor William R. Roush.
“Our new ADCs are built something like a double-decker bus,” Rader said. “The upper deck is a targeting antibody that locks onto a cancer cell, while the lower deck is a catalytic antibody that carries the drug. This is yet another exciting application of an incredibly versatile class of catalytic antibodies originally developed by TSRI’s Carlos F. Barbas III and Richard A. Lerner in the 1990s.”
The name for this new technology is dual variable domain antibody-drug conjugates or DVD-ADCs.
Antibodies are large immune system proteins that recognize unique molecular markers on cancer cells called tumour antigens. On their own, antibodies are usually not potent enough to eradicate cancer. However, their high specificity for tumour antigens makes them ideal vehicles for drug delivery straight to cancer cells.
The new DVD-ADCs were used against HER2-driven breast cancer, as well as multiple myeloma and non-Hodgkin lymphoma, and the technology proved highly effective against all three types of cancers in both cell and animal model studies.
Not only is the new technology highly efficient, Rader explained, but it uses a modular assembly so it’s relatively simple to apply to different cancers and possibly to other diseases.
“The advantage is we can produce ADCs at a fast rate in a single step,” said Graduate Student Alex Nanna, first author of the study. “The DVD-ADC format brings everything together in a very efficient way.”
The DVD-ADCs take advantage of an unusually reactive amino acid residue, a natural lysine of the catalytic antibody. “We can tie drugs with high precision and stability to this residue and, what’s more, we can use it to monitor attachment because the antibody loses its catalytic activity when the drug attaches to the lysine. It’s a very clean and unique way to confirm successful ADC formation,” Rader said.
The technology also eliminates the need to purify the antibody during initial production, postponing that process until the ADC is assembled. “From a manufacturing point of view, this is a substantial advantage.” Rader said.
There are currently only four FDA-approved ADCs for cancer therapy, of which two have been added this year alone.
“There is new excitement in this field,” Rader said. “One ADC was recently approved in acute lymphoblastic leukaemia and there’s a rich clinical and preclinical pipeline.”
Article adapted from a TSRI news release.
Publication: Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. Alex R. Nanna et al. Nature Communications (2017): Click here to view.